secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0000872589-25-000026
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q3'25: Revenue $3.75B (+1%), GAAP EPS $13.62, Non-GAAP EPS $11.83; EYLEA sales down 28%
--------------------------------------------------------------------------------

- Total revenue $3.754B (+1% YoY); GAAP EPS $13.62 (+18%), non-GAAP EPS $11.83 (-5%).
- Dupixent global net sales (Sanofi) up 27% to $4.86B; total EYLEA HD+EYLEA U.S. down 28% to $1.11B.
- FDA approved Libtayo for adjuvant CSCC; positive Phase 3 data for cemdisiran in myasthenia gravis and DB-OTO gene therapy in hearing loss.
- 2025 guidance revised: GAAP R&D $5.68-5.75B, GAAP SG&A $2.775-2.845B, gross margin about 82%, ETR about 14%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/0000872589-25-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/regn-20251028.htm
  HTML page:      https://secwatch.observer/filing/0000872589-25-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer